Wolfe Research Upgrades Immunovant to Outperform with $50 Target
Wolfe Research upgrades Immunovant stock, citing higher valuation support, declining short interest, and positive catalysts ahead in 2026.
/ 2 items
Wolfe Research upgrades Immunovant stock, citing higher valuation support, declining short interest, and positive catalysts ahead in 2026.
argenx discontinues Phase 3 trials of efgartigimod SC for thyroid eye disease after independent review finds treatment unlikely to meet goals. Safety profile remained favorable.